Anti-NGF antibodies and anti-NGF antibody fragments

Patent metadata

Field	Value
Publication number	US-10227402-B2
Application number	US-201715655478-A
Country	US
Kind code	B2
Filing date	Jul 20, 2017
Priority date	Dec 1, 2010
Publication date	Mar 12, 2019
Grant date	Mar 12, 2019

Abstract

Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.)

First claim

What is claimed is:

1. An anti-human NGF antibody or fragment thereof, wherein the anti-NGF antibody or antibody fragment specifically binds human NGF and comprises variable light chain CDR polypeptides having the sequences of SEQ ID NO: 135; SEQ ID NO: 136; and SEQ ID NO: 137 and variable heavy chain CDR polypeptides having the sequences of SEQ ID NO: 138; SEQ ID NO: 139; and SEQ ID NO: 140.

2. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable light chain having at least 90% sequence identity to SEQ ID NO: 131.

3. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable heavy chain having at least 90% sequence identity to SEQ ID NO: 133.

4. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable light chain having at least 90% sequence identity to SEQ ID NO: 131 and a variable heavy chain having at least 90% sequence identity to SEQ ID NO: 133.

5. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable light chain having at least 95% sequence identity to SEQ ID NO: 131.

6. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable heavy chain having at least 95% sequence identity to SEQ ID NO: 133.

7. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable light chain having at least 95% sequence identity to SEQ ID NO: 131 and a a variable heavy chain having at least 95% sequence identity to SEQ ID NO: 133.

8. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable light chain having the sequence of SEQ ID NO: 131.

9. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable heavy chain having the sequence of SEQ ID NO: 133.

10. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a variable light chain having the sequence of SEQ ID NO: 131 and a variable heavy chain having the sequence of SEQ ID NO: 133.

11. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a light chain having the sequence of SEQ ID NO: 132 and a heavy chain having the sequence of SEQ ID NO: 134.

12. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment is chimeric or humanized.

13. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises human constant domains.

14. The anti-human NGF antibody or fragment thereof of claim 13 , wherein the human constant domains are selected from human IgG1, IgG2, IgG3 and IgG4 constant domains.

15. The anti-human NGF antibody or fragment thereof of claim 13 , wherein the human constant domains comprise human IgG1 constant domains.

16. The anti-human NGF antibody or fragment thereof of claim 13 , wherein the human constant domains do not elicit ADCC.

17. The anti-human NGF antibody or fragment thereof of claim 13 , wherein the human constant domains do not elicit complement activation.

18. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a Fab, Fab′, F(ab′) 2 , Fv, scFv, IgNAR or a nanobody.

19. The anti-human NGF antibody or fragment thereof of claim 1 , wherein the anti-NGF antibody or antibody fragment comprises a Fab.

Assignees

• Alderbio Holdings Llc

Inventors

• Garcia-Martinez Leon F
• Latham John
• Ojala Ethan W
• Akatsuka Corinne C
• Fan Pei
• Smith Jeffrey T L
• Dutzar Benjamin H

Classifications

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K16/22 Primary

  against growth factors {; against growth regulators} · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K16/2875

  against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241) · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title